Products & Services

iCell® Hepatocytes 2.0

Investigate Liver Disease with Human Hepatocytes

The medical community needs a reproducible, well-characterized, and readily available source of human hepatocytes to advance significantly the launch of new metabolic and infectious disease therapies, reduce the incidence of drug-induced liver injury, and accelerate the development of novel approaches to liver regeneration and transplantation.

To meet this need, CDI has leveraged iPS cell technology  to develop iCell® Hepatocytes. These hepatocytes overcome the functionality, reproducibility, and availability limitations of existing primary cell and tumor-derived cell models by providing the following:

  • Relevant hepatic functionality and phenotypic stability
  • Expression of clinical targets that are relevant for liver and metabolic disease
  • Compatibility with a wide range of 3D and microphysiological systems
  • Quality-controlled manufacturing and batch reproducibility
  • Ready supply in a cryopreserved format

Proven Applications

iCell Hepatocytes 2.0 are being rapidly adopted for use in a wide range of applications:

  • Diabetes research and drug discovery
    Functional INS and glucose regulation pathways and a flexible product format enable high-throughput screening for novel drug candidates.
  • Hepatotoxicity assessment
    Known genetic background and proven ability to detect metabolism-dependent and immune-mediated hepatotoxicity provide confidence in safety testing without the need for time-consuming and costly lot testing (Sirenko et al., 2013; Mann, 2014; Lu et al., 2015).